Giant cell tumor of the calvaria in a child

1994 ◽  
Vol 80 (1) ◽  
pp. 148-151 ◽  
Author(s):  
Lee Reed ◽  
Crystl D. Willison ◽  
Sydney S. Schochet ◽  
Joseph L. Voelker
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Stromal Cells ◽  
Giant Cells ◽  
Cellular Tissue ◽  
Cell Tumor ◽  
Content Type ◽  
History Of ◽  
Rare Lesion ◽  
Fine Print

✓ A giant cell tumor involving the vertex of the skull is described in a 3-year-old child with no history of head trauma. The mass was present approximately 4 months prior to resection. Microscopically, the lesion consisted of highly cellular tissue composed of oval to spindle-shaped stromal cells admixed with numerous multinucleated giant cells. Giant cell tumor of the skull is a rare lesion, usually involving the sphenoid or temporal bone in adults. The differential diagnosis is discussed with reference to the literature regarding giant cell lesions, especially of the cranium. The authors are unaware of previous reports of a similar lesion in this location in such a young child.

Villonodular synovitis in the spinal canal

1980 ◽  
Vol 52 (6) ◽  
pp. 846-848 ◽  
Author(s):  
George M. Kleinman ◽  
T. Forcht Dagi ◽  
Charles E. Poletti
Keyword(s):  
Giant Cell Tumor ◽  
Spinal Canal ◽  
Giant Cells ◽  
Cell Tumor ◽  
Villonodular Synovitis ◽  
Rare Occurrence ◽  
Multinucleated Giant Cells ◽  
Content Type ◽  
Synovial Tissues ◽  
Fine Print

✓ Villonodular synovitis is believed to be an inflammatory, proliferative reaction of synovial tissues. The case of a 65-year-old woman with a cervical epidural mass is presented in which histological examination showed that the lesion was villonodular synovitis, an extremely rare occurrence. Because of its cellularity and occasional multinucleated giant cells, villonodular synovitis may be confused with metastatic malignancies or giant-cell tumor of bone.

scholarly journals Giant cell tumor stromal cells: osteoblast lineage-derived cells secrete IL-6 and IL-10 for M2 macrophages polarization

PeerJ ◽  
2020 ◽  
Vol 8 ◽  
pp. e9748
Author(s):  
Kuan Yang ◽  
Lihui Bao ◽  
Xiaoning He ◽  
Wanmin Zhao ◽  
Dongdong Fei ◽  
...  
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Stromal Cells ◽  
Macrophage Polarization ◽  
Giant Cells ◽  
Interleukin 10 ◽  
Cell Tumor ◽  
M2 Macrophages ◽  
M2 Polarization ◽  
Macrophages Polarization

Background The giant cell tumor (GCT) is a benign tumor which consists of three types cells: mononuclear histiocytic cells (MNHCs), multinuclear giant cells (MNGCs), and GCT stromal cells (GCTSCs). Numerous studies claim that GCTSCs have mesenchymal stem cells (MSCs) characters and play an important role in osteoclastogenesis; however, there are no research studies concerning macrophage polarization among GCT, which can be regarded as an ingredient for tumor aggression. Method We tested the effect of GCTSCs from three GCT samples which were collected from patients on proliferation, apoptosis and polarization of macrophage. Result In this article, we verified that GCTSCs expressed MSCs markers and had higher proliferation and relative lower differentiation abilities compared with BMMSCs. What’s more, we found a higher proportion of M2 macrophages among neoplasm. Co-culturing GCTSCs with macrophages resulted in prominent macrophage M2 polarization and increased the release of IL-6 (Interleukin-6) and IL-10 (Interleukin-10)from GCTSCs. In conclusion, GCTSCs, as originating from MSCs, can secret IL-6 and IL-10, which may play a significant role in macrophage M2 polarization.

Histomorphometric Analysis of Pre- and Post-Denosumab–Treated Giant Cell Tumor of Bone

2020 ◽  
Vol 28 (8) ◽  
pp. 859-867
Author(s):  
Nasir Ud Din ◽  
Masood Umer ◽  
Yong-Koo Park
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Stromal Cells ◽  
Mononuclear Cells ◽  
Giant Cells ◽  
Cell Tumor ◽  
P Value ◽  
Osteoblastic Activity ◽  
Woven Bone ◽  
Hematoxylin And Eosin

Context. Denosumab is a monoclonal antibody against RANK ligand. Its administration in giant cell tumor of bone (GCTB) cases results in elimination of giant cells and new bone formation. Neoplastic stromal cells of GCTB harbor mutation of histone 3.3 and have pre-osteoblastic properties and thus express SATB2. Objectives. To (1) analyze histological changes in post-denosumab–treated GCTB, (2) analyze expression of H3.3G34W and SATB2 in pre- and post-denosumab–treated samples, and (3) to discuss why changes occur in the expression of not only H3.3G34W but also SATB2. Materials and Methods. Hematoxylin and eosin slides of 19 cases of denosumab-treated GCTB were reviewed. Immunohistochemical stains H3.3G34W and SATB2 were performed. The number of positive mononuclear cells were counted and graded. Results. Complete absence of osteoclast-like giant cells (OCLGCs) was noted in most cases along with a fibro-osseous component merging with peripheral shell of reactive bone. Irregular trabeculae of woven bone and osteoid with focal osteoblastic rimming was seen. Spindle cells were arranged predominantly in fascicular pattern. Morphometric analysis of H3.3G34W showed a mean of 68.8% positive stromal cells in pretreatment and a mean of 26.9% positive stromal cells in posttreated specimens with a statistically significant P value (.001). Mean percentage of SATB2-positive stromal cells in the pre- and posttreatment specimens was 36.46% and 20.8%, respectively. Conclusions. Our study validates that denosumab treatment results in marked reduction of OCLGCs with increased osteoblastic activity. Decreased expression of H3.3G34W in posttreatment may be a result of decreased antigenicity of neoplastic mononuclear cells. No significant change in SATB2 expression was noted.

Tenosynovial giant-cell tumor of the cervical spine

1992 ◽  
Vol 77 (6) ◽  
pp. 952-955 ◽  
Author(s):  
Asim Mahmood ◽  
Dario V. Caccamo ◽  
Jay K. Morgan
Keyword(s):  
Cervical Spine ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor ◽  
Disease Entity ◽  
Content Type ◽  
Tenosynovial Giant Cell Tumor ◽  
Radiological Features ◽  
Fine Print

✓ A case of tenosynovial giant-cell tumor affecting the cervical spine is reported. The lesion is seen primarily in the fingers, knee, or ankle, and there are no previous reports of it occurring in the spine. The histological and radiological features of this tumor are discussed along with a brief description of the disease entity.

Giant-cell tumor of the middle cranial fossa

1987 ◽  
Vol 66 (6) ◽  
pp. 924-928 ◽  
Author(s):  
J. Max Findlay ◽  
David Chiasson ◽  
Alan R. Hudson ◽  
Mario Chui
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Adjuvant Radiotherapy ◽  
Middle Cranial Fossa ◽  
Cell Tumor ◽  
Content Type ◽  
Cranial Fossa ◽  
The Right ◽  
Fine Print

✓ The authors report the case of a 23-year-old man with a giant-cell tumor of the right middle cranial fossa floor. His presentation and management are described, and some aspects of this rare neoplasm of the skull base are reviewed. The role of adjuvant radiotherapy is discussed.

scholarly journals Successful Intravascular Correction of Intratumoral Pseudoaneurysm by Erosion of the Aorta in a Patient with Thoracic Giant Cell Tumor of Bone Responding to Denosumab

2015 ◽  
Vol 2015 ◽  
pp. 1-5
Author(s):  
Natalia M. P. Fraile ◽  
Diego Toloi ◽  
Ceci O. Kurimori ◽  
Adriana R. B. Matutino ◽  
Alberto Codima ◽  
...  
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Stromal Cells ◽  
Giant Cells ◽  
Cell Tumor ◽  
Significant Activity ◽  
Receptor Activator ◽  
Endovascular Approach ◽  
Nuclear Factor Kb ◽  
Recent Demonstration

Giant cell tumor of bone (GCT) is a rare, locally aggressive neoplasm characterized by the presence of giant cells with osteoclast activity. Its biology involves the overexpression of theReceptor Activator of Nuclear Factor kB Ligand(RANKL) by osteoclast-like giant cells and tumor stromal cells, which has been shown to be an actionable target in this disease. In cases amenable to surgical resection, very few therapeutic options were available until the recent demonstration of significant activity of the anti-RANK-ligand monoclonal antibody denosumab. Here we present a case of a patient with advanced GCT arising in the spine, recurring after multiple resections and embolization. Following initiation of denosumab, which resulted in unequivocal clinical improvement, computed tomography of the chest done for reassessment purposes revealed an intratumoral pseudoaneurysm by erosion of the aorta, further corrected by endovascular approach and stent placement. Patient had an unremarkable recovery from the procedure and continued benefit from therapy with denosumab and remains on treatment 24 months after the first dose.

scholarly journals New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRβ Signaling

Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3543
Author(s):  
Michal Mahdal ◽  
Jakub Neradil ◽  
Peter Mudry ◽  
Silvia Paukovcekova ◽  
Iva Staniczkova Zambo ◽  
...  
Keyword(s):  
Growth Factor ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Stromal Cells ◽  
Growth Factor Receptor ◽  
Metastatic Potential ◽  
Giant Cells ◽  
Cell Tumor ◽  
Primary Bone Tumor

Giant-cell tumor of bone (GCTB) is an intermediate type of primary bone tumor characterized by locally aggressive growth with metastatic potential. The aim of this study was to identify new druggable targets among the cell signaling molecules involved in GCTB tumorigenesis. Profiles of activated signaling proteins in fresh-frozen tumor samples and tumor-derived cell lines were determined using phosphoprotein arrays. Analysis of the obtained data revealed epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor beta (PDGFRβ) as potential targets, but only the PDGFR inhibitor sunitinib caused a considerable decrease in stromal cell viability in vitro. Furthermore, in the case of a 17-year-old patient suffering from GCTB, we showed that the addition of sunitinib to the standard treatment of GCTB with the monoclonal antibody denosumab resulted in the complete depletion of multinucleated giant cells and mononuclear stromal cells in the tumor tissue. To summarize, the obtained data showed that a specific receptor tyrosine kinase (RTK) signaling pattern is activated in GCTB cells and plays an important role in the regulation of cell proliferation. Thus, activated RTKs and their downstream signaling pathways represent useful targets for precision treatment with low-molecular-weight inhibitors or with other types of modern biological therapy.

scholarly journals Giant cell tumor in adipose package Hoffa

2017 ◽  
Vol 5 (1_suppl) ◽  
pp. 2325967117S0003
Author(s):  
H. Rivarola Etcheto ◽  
G. Escobar ◽  
C. Collazo Blanchod ◽  
M. Palanconi ◽  
J. Zordan ◽  
...  
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Pediatric Patients ◽  
Knee Laxity ◽  
Tendon Sheath ◽  
Giant Cells ◽  
Cellular Tissue ◽  
Cell Tumor ◽  
Joint Effusion ◽  
Giant Cell Tumors

Tumors of adipose Hoffa package are very uncommon, with isolated cases reported in the literature. His presentation in pediatric patients knee is exceptional. The most frequently described tumors are benign including vellonodular synovitis. The extra-articular localized variant there of is known as giant cell tumor of the tendon sheath. It is characterized by locally aggressive nature, and has been described in reports of isolated cases. Objective: A case of giant cell tumor of the tendon sheath in adipose presentation package Hoffa in pediatric patients is presented in this paper. Methods: male patient eleven years with right knee pain after sports practice was evaluated. Physical examination, showed limited extension -30º, joint effusion, stable negative Lachman maneuver without peripheral knee laxity. MRI hyperintense on tumor is observed in T2 and hypointense on T1 homogeneous and defined edges content displayed prior to LCA related to adipose Hoffa package. Results: The tumor specimen was obtained and histopathology is defined as densely cellular tissue accumulation of xantomisados fibrocollagenous with histiocytes and multinucleated giant cells, compatible with giant cell tumor of tendon sheath. Conclusion: The presentation of giant cell tumors of the tendon sheath in Hoffa fat pad is exceptional. However, his suspicion allows adequate preoperative surgical planning, as a whole resection is the only procedure that has been shown to decrease the rate of recurrence of this disease.

scholarly journals Benign giant cell tumor of bone with pulmonary metastasis- report of two cases and review of literature

2017 ◽  
Vol 5 (3) ◽  
pp. 1131
Author(s):  
Geethu G. Nair ◽  
Rajan G. ◽  
Supriya N. K. ◽  
Sathi P. P.
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Pulmonary Metastasis ◽  
Past History ◽  
Bone Lesion ◽  
Giant Cells ◽  
Tumor Location ◽  
Cell Tumor ◽  
Sarcomatous Transformation ◽  
History Of

Tumors that are metastasizing generally considered as malignant. But there are exceptions. Giant cell tumor of bone is well known for its potential to metastasize without sarcomatous transformation. Potential of benign GCT to metastasize was first reported by Jaffe et al in 1940. Prevalence of pulmonary metastasis in benign GCT is between 1-9%. Factors favoring metastasis include recurrence of tumor, surgical manipulation of initial bone tumor, location of femur etc. Peripheral or basilar portion of pulmonary parenchyma is involved commonly. Eventhough death reported in 16-25% of cases, overall it has a favorable prognosis. Surgical resection is preferred treatment for pulmonary metastasis. In the present study 2 case studies were done. In 1st study 18 year old female, known case of GCT Lt tibia, with history of curetting and cementing presented with pain and swelling at same site and pulmonary metastasis 1 year later. Biopsy from initial as well as recurrent tumor confirmed benign GCT without any features of atypia, mitosis or necrosis. Aspirate from pulmonary lesion showed osteoclastic giant cells. No treatment given to metastatic deposits and is asymptomatic even though size of pulmonary lesions is increasing. And in second study a 22 year old female, with past history of GCT referred to our institution for evaluation of lung lesion detected in X-ray. Patient underwent metastatectomy here and histopathology was similar to that of bone lesion. There was no evidence of sarcomatous transformation both in initial and recurrent lesion. Patient is asymptomatic other wise and doing well.

Sign in / Sign up

Export Citation Format

Share Document